EMA product information as a primary source posts 61–75

This follows post #58 rather than contradicting it.

Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.

I read post #60 twice before replying, because I had assumed the opposite.

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

Picking up post #62: that is the part I would want checked first.

France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.

Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.

Worth separating two things that post #67 runs together.

Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.